Laura Saba
Concepts (683)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Stenosis | 8 | 2020 | 91 | 3.610 |
Why?
| | Plaque, Atherosclerotic | 4 | 2020 | 57 | 2.380 |
Why?
| | Alcohol Drinking | 18 | 2021 | 821 | 1.940 |
Why?
| | Quantitative Trait Loci | 25 | 2025 | 382 | 1.820 |
Why?
| | Carotid Arteries | 5 | 2020 | 209 | 1.590 |
Why?
| | Ethanol | 16 | 2024 | 608 | 1.390 |
Why?
| | Transcriptome | 9 | 2025 | 972 | 1.290 |
Why?
| | Brain | 22 | 2025 | 2675 | 1.290 |
Why?
| | Gene Regulatory Networks | 7 | 2023 | 309 | 1.260 |
Why?
| | Adrenocortical Carcinoma | 7 | 2025 | 65 | 1.190 |
Why?
| | High-Throughput Nucleotide Sequencing | 7 | 2024 | 537 | 1.090 |
Why?
| | Adrenal Cortex Neoplasms | 6 | 2025 | 63 | 1.060 |
Why?
| | Quantitative Trait, Heritable | 7 | 2017 | 127 | 1.040 |
Why?
| | Gene Expression Profiling | 16 | 2021 | 1774 | 1.010 |
Why?
| | Rats, Inbred Strains | 7 | 2019 | 362 | 0.940 |
Why?
| | Mitotane | 6 | 2025 | 10 | 0.900 |
Why?
| | Systems Biology | 3 | 2021 | 66 | 0.890 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2025 | 193 | 0.870 |
Why?
| | Myocarditis | 1 | 2025 | 101 | 0.870 |
Why?
| | Trace Elements | 2 | 2021 | 51 | 0.850 |
Why?
| | Hemorrhage | 2 | 2019 | 723 | 0.850 |
Why?
| | Genetic Predisposition to Disease | 13 | 2024 | 2419 | 0.800 |
Why?
| | Liver | 10 | 2024 | 1941 | 0.790 |
Why?
| | Rats | 22 | 2025 | 5639 | 0.790 |
Why?
| | Cerebrovascular Disorders | 2 | 2022 | 96 | 0.780 |
Why?
| | Atrial Appendage | 1 | 2022 | 17 | 0.750 |
Why?
| | MicroRNAs | 6 | 2019 | 699 | 0.720 |
Why?
| | Precision Medicine | 1 | 2025 | 428 | 0.710 |
Why?
| | Polymorphism, Single Nucleotide | 18 | 2025 | 2195 | 0.700 |
Why?
| | Sequence Analysis, RNA | 7 | 2022 | 452 | 0.700 |
Why?
| | Polyadenylation | 1 | 2021 | 42 | 0.680 |
Why?
| | Protein Carbonylation | 7 | 2019 | 54 | 0.680 |
Why?
| | Phenotype | 15 | 2020 | 3202 | 0.670 |
Why?
| | RNA | 6 | 2021 | 924 | 0.670 |
Why?
| | Animals | 61 | 2025 | 36862 | 0.660 |
Why?
| | RNA, Long Noncoding | 2 | 2020 | 181 | 0.660 |
Why?
| | Liver Diseases, Alcoholic | 5 | 2024 | 93 | 0.650 |
Why?
| | Atherosclerosis | 2 | 2021 | 415 | 0.630 |
Why?
| | Adipose Tissue | 2 | 2020 | 630 | 0.620 |
Why?
| | Software | 8 | 2025 | 667 | 0.610 |
Why?
| | Cerebral Hemorrhage | 1 | 2019 | 112 | 0.600 |
Why?
| | Drug Tolerance | 4 | 2020 | 105 | 0.600 |
Why?
| | Tunica Media | 1 | 2018 | 38 | 0.570 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2025 | 161 | 0.570 |
Why?
| | Tunica Intima | 1 | 2018 | 84 | 0.560 |
Why?
| | Genetic Variation | 5 | 2024 | 988 | 0.550 |
Why?
| | Databases, Genetic | 5 | 2017 | 237 | 0.550 |
Why?
| | Male | 76 | 2025 | 67560 | 0.540 |
Why?
| | Complement C3 | 5 | 2024 | 209 | 0.540 |
Why?
| | Alcohol-Related Disorders | 1 | 2018 | 124 | 0.530 |
Why?
| | Tomography, X-Ray Computed | 8 | 2021 | 2679 | 0.530 |
Why?
| | Magnetic Resonance Imaging | 5 | 2025 | 3568 | 0.520 |
Why?
| | Humans | 98 | 2025 | 137294 | 0.490 |
Why?
| | Genomics | 6 | 2024 | 792 | 0.490 |
Why?
| | Alcoholism | 8 | 2021 | 806 | 0.490 |
Why?
| | Brain Ischemia | 1 | 2019 | 343 | 0.490 |
Why?
| | Middle Aged | 44 | 2025 | 33310 | 0.480 |
Why?
| | Central Nervous System Depressants | 4 | 2010 | 85 | 0.470 |
Why?
| | Female | 71 | 2025 | 73052 | 0.460 |
Why?
| | Computed Tomography Angiography | 3 | 2021 | 125 | 0.450 |
Why?
| | Angiography | 4 | 2010 | 207 | 0.450 |
Why?
| | Models, Statistical | 1 | 2018 | 670 | 0.440 |
Why?
| | Aged, 80 and over | 13 | 2024 | 7607 | 0.430 |
Why?
| | Aged | 29 | 2024 | 23851 | 0.430 |
Why?
| | Internet | 6 | 2010 | 651 | 0.420 |
Why?
| | Retrospective Studies | 18 | 2025 | 15639 | 0.400 |
Why?
| | Mustard Gas | 2 | 2025 | 103 | 0.400 |
Why?
| | Mice | 34 | 2025 | 17774 | 0.400 |
Why?
| | Chemical Warfare Agents | 2 | 2025 | 114 | 0.400 |
Why?
| | Oligonucleotide Array Sequence Analysis | 6 | 2019 | 767 | 0.400 |
Why?
| | Complement Activation | 4 | 2025 | 411 | 0.400 |
Why?
| | Bayes Theorem | 5 | 2020 | 401 | 0.390 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 63 | 0.380 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2836 | 0.380 |
Why?
| | Genome-Wide Association Study | 3 | 2025 | 1434 | 0.370 |
Why?
| | Genome | 4 | 2024 | 291 | 0.360 |
Why?
| | Adult | 42 | 2025 | 37724 | 0.350 |
Why?
| | Ultrasonography | 3 | 2020 | 752 | 0.350 |
Why?
| | Aldehydes | 5 | 2019 | 145 | 0.340 |
Why?
| | Glutathione Transferase | 4 | 2019 | 105 | 0.340 |
Why?
| | Mice, Inbred Strains | 9 | 2020 | 409 | 0.330 |
Why?
| | Health Education | 3 | 2008 | 338 | 0.320 |
Why?
| | ROC Curve | 4 | 2019 | 548 | 0.320 |
Why?
| | Oxidative Stress | 6 | 2025 | 1315 | 0.310 |
Why?
| | Dexamethasone | 3 | 2025 | 377 | 0.310 |
Why?
| | Endometriosis | 2 | 2020 | 50 | 0.310 |
Why?
| | Carotid Artery Diseases | 1 | 2009 | 66 | 0.310 |
Why?
| | Rats, Wistar | 3 | 2020 | 455 | 0.300 |
Why?
| | Genetic Association Studies | 5 | 2017 | 377 | 0.300 |
Why?
| | Tomography, Spiral Computed | 1 | 2008 | 32 | 0.290 |
Why?
| | Synaptic Transmission | 1 | 2010 | 289 | 0.290 |
Why?
| | Nanoparticles | 4 | 2025 | 484 | 0.290 |
Why?
| | Brain Diseases | 1 | 2009 | 141 | 0.280 |
Why?
| | Models, Genetic | 6 | 2025 | 607 | 0.280 |
Why?
| | Tandem Mass Spectrometry | 5 | 2024 | 532 | 0.260 |
Why?
| | Genotype | 11 | 2025 | 1923 | 0.260 |
Why?
| | Point Mutation | 2 | 2001 | 235 | 0.260 |
Why?
| | Contrast Media | 5 | 2021 | 462 | 0.260 |
Why?
| | Breast Neoplasms | 6 | 2023 | 2243 | 0.260 |
Why?
| | Genes, Regulator | 1 | 2006 | 37 | 0.260 |
Why?
| | beta-Thalassemia | 4 | 2013 | 36 | 0.250 |
Why?
| | PTEN Phosphohydrolase | 2 | 2018 | 162 | 0.250 |
Why?
| | Adenylyl Cyclases | 3 | 2012 | 87 | 0.250 |
Why?
| | Gene Expression Regulation | 8 | 2025 | 2608 | 0.240 |
Why?
| | Smoking Prevention | 1 | 2006 | 186 | 0.240 |
Why?
| | Iron | 2 | 2021 | 313 | 0.240 |
Why?
| | Activating Transcription Factor 3 | 1 | 2025 | 5 | 0.240 |
Why?
| | Rats, Inbred SHR | 4 | 2018 | 45 | 0.230 |
Why?
| | Activating Transcription Factor 4 | 1 | 2025 | 20 | 0.230 |
Why?
| | Limbus Corneae | 1 | 2025 | 8 | 0.230 |
Why?
| | Phytochemicals | 1 | 2025 | 13 | 0.230 |
Why?
| | Tea | 1 | 2025 | 21 | 0.230 |
Why?
| | Recombination, Genetic | 2 | 2017 | 199 | 0.230 |
Why?
| | Nanomedicine | 1 | 2025 | 47 | 0.230 |
Why?
| | Hypothalamo-Hypophyseal System | 4 | 2017 | 197 | 0.230 |
Why?
| | Mice, Inbred C57BL | 12 | 2025 | 5753 | 0.220 |
Why?
| | Doxorubicin | 3 | 2025 | 365 | 0.220 |
Why?
| | Endarterectomy, Carotid | 2 | 2017 | 49 | 0.220 |
Why?
| | Polyethylene Glycols | 3 | 2025 | 640 | 0.220 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2025 | 109 | 0.220 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 162 | 0.220 |
Why?
| | Algorithms | 4 | 2023 | 1692 | 0.220 |
Why?
| | Heart Transplantation | 2 | 2021 | 747 | 0.220 |
Why?
| | Stents | 1 | 2008 | 529 | 0.220 |
Why?
| | Magnesium | 2 | 2021 | 158 | 0.210 |
Why?
| | Cysteine | 1 | 2024 | 205 | 0.210 |
Why?
| | Corneal Injuries | 1 | 2024 | 44 | 0.210 |
Why?
| | Base Sequence | 6 | 2021 | 2182 | 0.200 |
Why?
| | Analgesia | 1 | 2024 | 94 | 0.200 |
Why?
| | Germ-Line Mutation | 1 | 2024 | 172 | 0.200 |
Why?
| | Sensitivity and Specificity | 4 | 2019 | 1946 | 0.200 |
Why?
| | Immunoglobulins | 2 | 2024 | 171 | 0.200 |
Why?
| | Lysine | 1 | 2024 | 294 | 0.190 |
Why?
| | Rats, Inbred BN | 3 | 2018 | 58 | 0.190 |
Why?
| | Receptors, GABA-A | 2 | 2018 | 142 | 0.190 |
Why?
| | Whole Genome Sequencing | 2 | 2024 | 153 | 0.190 |
Why?
| | Acute Disease | 1 | 2025 | 1009 | 0.190 |
Why?
| | Dextrans | 2 | 2024 | 84 | 0.190 |
Why?
| | Immunoconjugates | 1 | 2023 | 114 | 0.190 |
Why?
| | Phosphorus | 2 | 2021 | 97 | 0.190 |
Why?
| | Fetal Development | 2 | 2022 | 296 | 0.190 |
Why?
| | Behavior, Addictive | 2 | 2020 | 82 | 0.190 |
Why?
| | Multifactorial Inheritance | 2 | 2025 | 174 | 0.180 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 17 | 0.180 |
Why?
| | Signal Transduction | 8 | 2025 | 5078 | 0.180 |
Why?
| | Leukopenia | 1 | 2021 | 31 | 0.180 |
Why?
| | Proteome | 3 | 2024 | 472 | 0.180 |
Why?
| | Heart Atria | 1 | 2022 | 136 | 0.180 |
Why?
| | Magnesium Deficiency | 1 | 2020 | 1 | 0.180 |
Why?
| | Selenium | 1 | 2021 | 39 | 0.180 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 498 | 0.180 |
Why?
| | Chromatography, Liquid | 5 | 2024 | 432 | 0.180 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2021 | 130 | 0.180 |
Why?
| | Myocardium | 2 | 2018 | 1002 | 0.170 |
Why?
| | Protein Processing, Post-Translational | 3 | 2024 | 467 | 0.170 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 117 | 0.170 |
Why?
| | Copper | 1 | 2021 | 108 | 0.170 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 94 | 0.170 |
Why?
| | Hydroxycholesterols | 1 | 2020 | 5 | 0.170 |
Why?
| | Stem Cells | 1 | 2025 | 593 | 0.170 |
Why?
| | Complement System Proteins | 2 | 2024 | 327 | 0.170 |
Why?
| | Sigmoid Diseases | 1 | 2020 | 12 | 0.170 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2020 | 15 | 0.170 |
Why?
| | Rectal Diseases | 1 | 2020 | 23 | 0.160 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2019 | 9 | 0.160 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2019 | 23 | 0.160 |
Why?
| | Osteoprotegerin | 3 | 2009 | 24 | 0.160 |
Why?
| | Epithelium, Corneal | 1 | 2019 | 41 | 0.160 |
Why?
| | Risk | 2 | 2021 | 908 | 0.160 |
Why?
| | User-Computer Interface | 1 | 2020 | 160 | 0.160 |
Why?
| | Drosophila | 1 | 2020 | 151 | 0.160 |
Why?
| | Pesticides | 1 | 2019 | 61 | 0.160 |
Why?
| | Pancreatic Diseases | 1 | 2020 | 72 | 0.160 |
Why?
| | Liposomes | 2 | 2019 | 220 | 0.160 |
Why?
| | Genetic Markers | 1 | 2020 | 344 | 0.160 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2022 | 616 | 0.160 |
Why?
| | Anthracenes | 1 | 2019 | 31 | 0.160 |
Why?
| | Reflex, Righting | 2 | 2018 | 15 | 0.150 |
Why?
| | Protein Corona | 1 | 2019 | 6 | 0.150 |
Why?
| | Opsonin Proteins | 1 | 2019 | 25 | 0.150 |
Why?
| | Mice, Inbred DBA | 5 | 2019 | 200 | 0.150 |
Why?
| | Acylation | 1 | 2019 | 31 | 0.150 |
Why?
| | Gene Expression | 3 | 2014 | 1501 | 0.150 |
Why?
| | Cushing Syndrome | 2 | 2010 | 10 | 0.150 |
Why?
| | Chimera | 1 | 2019 | 59 | 0.150 |
Why?
| | Biomarkers | 7 | 2020 | 4164 | 0.150 |
Why?
| | Fluorenes | 1 | 2019 | 42 | 0.150 |
Why?
| | Eicosanoids | 1 | 2019 | 62 | 0.150 |
Why?
| | Learning Curve | 1 | 2019 | 72 | 0.150 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 179 | 0.150 |
Why?
| | Drosophila Proteins | 1 | 2020 | 205 | 0.150 |
Why?
| | Sex Characteristics | 4 | 2021 | 765 | 0.150 |
Why?
| | Steroid 11-beta-Hydroxylase | 1 | 2018 | 1 | 0.150 |
Why?
| | Antioxidants | 2 | 2019 | 586 | 0.150 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3283 | 0.150 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 226 | 0.150 |
Why?
| | Hippocampus | 2 | 2022 | 895 | 0.150 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 116 | 0.150 |
Why?
| | Hallucinogens | 1 | 2020 | 105 | 0.150 |
Why?
| | Unsupervised Machine Learning | 1 | 2018 | 22 | 0.150 |
Why?
| | Cell Degranulation | 1 | 2018 | 41 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 251 | 0.140 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 114 | 0.140 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2020 | 213 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 109 | 0.140 |
Why?
| | Feasibility Studies | 1 | 2022 | 949 | 0.140 |
Why?
| | Lymphocytes | 1 | 2020 | 395 | 0.140 |
Why?
| | Angiography, Digital Subtraction | 1 | 2018 | 44 | 0.140 |
Why?
| | Zinc | 1 | 2021 | 298 | 0.140 |
Why?
| | Silver | 1 | 2018 | 40 | 0.140 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 117 | 0.140 |
Why?
| | Lung | 2 | 2021 | 4067 | 0.140 |
Why?
| | Receptors, Nicotinic | 1 | 2020 | 335 | 0.140 |
Why?
| | Food Preferences | 2 | 2009 | 119 | 0.140 |
Why?
| | Ferrosoferric Oxide | 1 | 2017 | 27 | 0.140 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2018 | 93 | 0.140 |
Why?
| | Computational Biology | 3 | 2017 | 646 | 0.140 |
Why?
| | Hepatitis | 1 | 2017 | 48 | 0.140 |
Why?
| | Adipose Tissue, Brown | 1 | 2017 | 53 | 0.140 |
Why?
| | Monocytes | 1 | 2020 | 563 | 0.140 |
Why?
| | Graft Rejection | 1 | 2021 | 620 | 0.140 |
Why?
| | Pancreas | 1 | 2020 | 329 | 0.140 |
Why?
| | Risk Factors | 6 | 2019 | 10368 | 0.140 |
Why?
| | Interleukin-6 | 3 | 2006 | 778 | 0.140 |
Why?
| | Smoking | 2 | 2020 | 1634 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 634 | 0.130 |
Why?
| | Web Browser | 1 | 2017 | 13 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2025 | 1399 | 0.130 |
Why?
| | Models, Animal | 1 | 2019 | 384 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 698 | 0.130 |
Why?
| | Gynecology | 1 | 2019 | 176 | 0.130 |
Why?
| | Globins | 2 | 1997 | 22 | 0.130 |
Why?
| | Mast Cells | 1 | 2018 | 147 | 0.130 |
Why?
| | Lod Score | 1 | 2016 | 67 | 0.130 |
Why?
| | Cholestasis | 1 | 2019 | 232 | 0.130 |
Why?
| | Chromosomes, Mammalian | 1 | 2016 | 25 | 0.130 |
Why?
| | Gene Ontology | 1 | 2016 | 53 | 0.130 |
Why?
| | Pain Threshold | 2 | 2010 | 74 | 0.130 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2016 | 12 | 0.130 |
Why?
| | Fatty Liver, Alcoholic | 1 | 2016 | 15 | 0.130 |
Why?
| | Opioid-Related Disorders | 1 | 2024 | 506 | 0.130 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2016 | 21 | 0.130 |
Why?
| | Seizures | 1 | 2020 | 430 | 0.130 |
Why?
| | Liver Diseases | 1 | 2019 | 311 | 0.130 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 82 | 0.130 |
Why?
| | Choice Behavior | 2 | 2014 | 171 | 0.130 |
Why?
| | Calcium | 2 | 2021 | 1198 | 0.130 |
Why?
| | Depressive Disorder, Major | 2 | 2012 | 362 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 2018 | 199 | 0.120 |
Why?
| | Mitochondria | 2 | 2021 | 947 | 0.120 |
Why?
| | von Willebrand Factor | 1 | 2016 | 81 | 0.120 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2015 | 17 | 0.120 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 269 | 0.120 |
Why?
| | beta Karyopherins | 1 | 2015 | 8 | 0.120 |
Why?
| | Databases, Nucleic Acid | 1 | 2015 | 34 | 0.120 |
Why?
| | Hydrocortisone | 4 | 2012 | 323 | 0.120 |
Why?
| | Anxiety | 1 | 2022 | 1036 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2021 | 741 | 0.120 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2015 | 38 | 0.120 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 87 | 0.120 |
Why?
| | Circadian Rhythm | 2 | 2020 | 468 | 0.120 |
Why?
| | Darkness | 1 | 2015 | 28 | 0.120 |
Why?
| | Immune System | 1 | 2016 | 177 | 0.120 |
Why?
| | Pulmonary Artery | 1 | 2021 | 1084 | 0.110 |
Why?
| | Allergens | 1 | 2018 | 408 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 434 | 0.110 |
Why?
| | Peptides | 1 | 2020 | 982 | 0.110 |
Why?
| | Consensus | 1 | 2018 | 680 | 0.110 |
Why?
| | Diet | 3 | 2008 | 1275 | 0.110 |
Why?
| | Down Syndrome | 1 | 2021 | 491 | 0.110 |
Why?
| | Neutrophils | 1 | 2020 | 1236 | 0.110 |
Why?
| | Early Detection of Cancer | 2 | 2023 | 419 | 0.110 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2017 | 279 | 0.110 |
Why?
| | Anti-HIV Agents | 1 | 2020 | 772 | 0.110 |
Why?
| | Mammography | 2 | 2006 | 152 | 0.110 |
Why?
| | Apoptosis | 2 | 2020 | 2554 | 0.110 |
Why?
| | Disease Models, Animal | 6 | 2024 | 4284 | 0.110 |
Why?
| | Species Specificity | 4 | 2014 | 585 | 0.110 |
Why?
| | LDL-Receptor Related Proteins | 1 | 2013 | 7 | 0.110 |
Why?
| | Proteomics | 4 | 2024 | 1108 | 0.110 |
Why?
| | Chloride Channels | 1 | 1993 | 35 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2018 | 2479 | 0.110 |
Why?
| | Oxidation-Reduction | 3 | 2024 | 1069 | 0.100 |
Why?
| | ErbB Receptors | 1 | 2017 | 613 | 0.100 |
Why?
| | Stroke | 1 | 2022 | 1134 | 0.100 |
Why?
| | Iron Overload | 1 | 2013 | 17 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1095 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 256 | 0.100 |
Why?
| | Genes | 1 | 1993 | 230 | 0.100 |
Why?
| | Chromosome Mapping | 4 | 2020 | 524 | 0.100 |
Why?
| | Database Management Systems | 2 | 2017 | 51 | 0.100 |
Why?
| | Glucocorticoids | 2 | 2009 | 596 | 0.100 |
Why?
| | Exercise | 3 | 2014 | 2045 | 0.100 |
Why?
| | Cannabis | 1 | 2020 | 493 | 0.100 |
Why?
| | Mice, Knockout | 5 | 2019 | 3009 | 0.100 |
Why?
| | Rabbits | 2 | 2025 | 793 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1058 | 0.100 |
Why?
| | Blood Pressure | 1 | 2020 | 1776 | 0.100 |
Why?
| | Catalase | 2 | 2017 | 131 | 0.100 |
Why?
| | Imaging, Three-Dimensional | 2 | 2015 | 577 | 0.100 |
Why?
| | Dogs | 2 | 2025 | 411 | 0.100 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2012 | 89 | 0.090 |
Why?
| | DNA Mutational Analysis | 4 | 2001 | 400 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5125 | 0.090 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2012 | 41 | 0.090 |
Why?
| | Metabolomics | 3 | 2025 | 679 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2015 | 361 | 0.090 |
Why?
| | Monoamine Oxidase | 1 | 2011 | 30 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1456 | 0.090 |
Why?
| | Kidney | 1 | 2019 | 1467 | 0.090 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3414 | 0.090 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2010 | 11 | 0.090 |
Why?
| | Receptors, GABA | 1 | 2010 | 14 | 0.090 |
Why?
| | Rats, Long-Evans | 2 | 2021 | 125 | 0.090 |
Why?
| | Area Under Curve | 3 | 2019 | 315 | 0.090 |
Why?
| | Inflammation | 4 | 2025 | 2836 | 0.090 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 422 | 0.090 |
Why?
| | Pituitary-Adrenal Function Tests | 1 | 2010 | 2 | 0.090 |
Why?
| | Hypertension | 1 | 2020 | 1285 | 0.090 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 267 | 0.090 |
Why?
| | Bone Density | 2 | 2012 | 487 | 0.080 |
Why?
| | Colonic Diseases, Functional | 2 | 2000 | 3 | 0.080 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1269 | 0.080 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 549 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1688 | 0.080 |
Why?
| | RNA, Messenger | 5 | 2018 | 2839 | 0.080 |
Why?
| | Postmenopause | 1 | 2012 | 365 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 939 | 0.080 |
Why?
| | United States | 4 | 2022 | 14742 | 0.080 |
Why?
| | Italy | 4 | 2019 | 109 | 0.080 |
Why?
| | Neoplasms | 2 | 2022 | 2661 | 0.080 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 994 | 0.080 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2009 | 10 | 0.080 |
Why?
| | Morphine | 1 | 2010 | 160 | 0.080 |
Why?
| | Logistic Models | 3 | 2010 | 2071 | 0.080 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2904 | 0.080 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2010 | 198 | 0.080 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 5436 | 0.080 |
Why?
| | Liver Neoplasms | 1 | 2015 | 785 | 0.080 |
Why?
| | Inflammation Mediators | 2 | 2024 | 514 | 0.080 |
Why?
| | RANK Ligand | 1 | 2008 | 29 | 0.080 |
Why?
| | Cyclooxygenase 2 | 2 | 2019 | 178 | 0.080 |
Why?
| | Iohexol | 1 | 2008 | 23 | 0.070 |
Why?
| | Aorta, Abdominal | 1 | 2008 | 46 | 0.070 |
Why?
| | Radiographic Image Enhancement | 1 | 2008 | 58 | 0.070 |
Why?
| | Breeding | 2 | 2014 | 62 | 0.070 |
Why?
| | Young Adult | 6 | 2024 | 13163 | 0.070 |
Why?
| | Blood Platelets | 1 | 2011 | 407 | 0.070 |
Why?
| | Scleroderma, Systemic | 1 | 2008 | 122 | 0.070 |
Why?
| | Vagina | 2 | 2020 | 186 | 0.070 |
Why?
| | Receptors, Glucocorticoid | 1 | 2009 | 155 | 0.070 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2007 | 54 | 0.070 |
Why?
| | Androgens | 1 | 2009 | 187 | 0.070 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2017 | 142 | 0.070 |
Why?
| | Alanine Transaminase | 2 | 2019 | 157 | 0.070 |
Why?
| | Electronic Mail | 1 | 2007 | 61 | 0.070 |
Why?
| | Observer Variation | 1 | 2008 | 345 | 0.070 |
Why?
| | Computer-Assisted Instruction | 1 | 2008 | 65 | 0.070 |
Why?
| | Mutation | 3 | 2017 | 3956 | 0.070 |
Why?
| | Hepatic Encephalopathy | 1 | 2007 | 21 | 0.070 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2008 | 140 | 0.070 |
Why?
| | Membrane Proteins | 1 | 1993 | 1163 | 0.070 |
Why?
| | Alcohol Dehydrogenase | 1 | 2006 | 16 | 0.070 |
Why?
| | Ovarian Neoplasms | 1 | 2012 | 565 | 0.060 |
Why?
| | Adrenal Cortex | 1 | 2006 | 29 | 0.060 |
Why?
| | Adolescent | 8 | 2020 | 21499 | 0.060 |
Why?
| | Cytokine Receptor gp130 | 1 | 2006 | 12 | 0.060 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 834 | 0.060 |
Why?
| | Computer Simulation | 2 | 2023 | 979 | 0.060 |
Why?
| | Superoxide Dismutase | 2 | 2019 | 346 | 0.060 |
Why?
| | Up-Regulation | 2 | 2019 | 844 | 0.060 |
Why?
| | Receptors, Interleukin-6 | 1 | 2006 | 43 | 0.060 |
Why?
| | Brain Chemistry | 2 | 2009 | 118 | 0.060 |
Why?
| | Prednisolone | 1 | 2006 | 83 | 0.060 |
Why?
| | Health Planning Guidelines | 1 | 2006 | 25 | 0.060 |
Why?
| | HIV Infections | 1 | 2020 | 2820 | 0.060 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2006 | 100 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2006 | 158 | 0.060 |
Why?
| | Culture | 1 | 2006 | 127 | 0.060 |
Why?
| | Program Evaluation | 2 | 2007 | 891 | 0.060 |
Why?
| | Bone Resorption | 1 | 2006 | 86 | 0.060 |
Why?
| | Alleles | 2 | 2019 | 892 | 0.060 |
Why?
| | Australia | 1 | 2006 | 314 | 0.060 |
Why?
| | Muscle Fatigue | 1 | 2006 | 102 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 308 | 0.060 |
Why?
| | Germ-Free Life | 1 | 2025 | 34 | 0.060 |
Why?
| | Ultraviolet Rays | 1 | 2008 | 390 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2021 | 4197 | 0.060 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2032 | 0.060 |
Why?
| | Health Promotion | 2 | 2008 | 737 | 0.060 |
Why?
| | Phosphorylation | 2 | 2019 | 1759 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2020 | 2486 | 0.060 |
Why?
| | Elective Surgical Procedures | 1 | 2006 | 180 | 0.060 |
Why?
| | Pregnancy | 4 | 2022 | 6743 | 0.060 |
Why?
| | Schools | 1 | 2008 | 465 | 0.050 |
Why?
| | Acetylation | 1 | 2024 | 248 | 0.050 |
Why?
| | Molecular Sequence Annotation | 1 | 2024 | 97 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 752 | 0.050 |
Why?
| | Oxycodone | 1 | 2024 | 44 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2494 | 0.050 |
Why?
| | Cystic Fibrosis | 1 | 1993 | 1104 | 0.050 |
Why?
| | Sports | 1 | 2006 | 231 | 0.050 |
Why?
| | Case-Control Studies | 4 | 2017 | 3546 | 0.050 |
Why?
| | Survival Rate | 2 | 2019 | 1970 | 0.050 |
Why?
| | Albumins | 1 | 2023 | 113 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 101 | 0.050 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2006 | 180 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3439 | 0.050 |
Why?
| | Plant Extracts | 1 | 2025 | 200 | 0.050 |
Why?
| | Environmental Exposure | 1 | 2008 | 577 | 0.050 |
Why?
| | Cornea | 1 | 2024 | 137 | 0.050 |
Why?
| | Leptin | 1 | 2004 | 236 | 0.050 |
Why?
| | Microarray Analysis | 2 | 2015 | 116 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 549 | 0.050 |
Why?
| | Prospective Studies | 4 | 2020 | 7595 | 0.050 |
Why?
| | Health Behavior | 1 | 2007 | 757 | 0.050 |
Why?
| | Mass Screening | 2 | 2010 | 1268 | 0.050 |
Why?
| | Patient Compliance | 1 | 2006 | 577 | 0.050 |
Why?
| | Feces | 1 | 2025 | 480 | 0.050 |
Why?
| | Epigenomics | 1 | 2022 | 115 | 0.050 |
Why?
| | Actins | 1 | 2024 | 416 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2008 | 1327 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2009 | 1034 | 0.050 |
Why?
| | Odds Ratio | 2 | 2020 | 1067 | 0.040 |
Why?
| | Rats, Inbred Lew | 1 | 2001 | 114 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 851 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2020 | 2147 | 0.040 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2020 | 4 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2017 | 10800 | 0.040 |
Why?
| | Iodine | 1 | 2021 | 27 | 0.040 |
Why?
| | Blotting, Western | 2 | 2015 | 1226 | 0.040 |
Why?
| | Curriculum | 1 | 2008 | 983 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2004 | 445 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 64 | 0.040 |
Why?
| | Time Factors | 4 | 2019 | 6818 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2001 | 271 | 0.040 |
Why?
| | Rats, Inbred F344 | 1 | 2001 | 264 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2006 | 1464 | 0.040 |
Why?
| | Oxysterols | 1 | 2020 | 2 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 2006 | 456 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 217 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2021 | 157 | 0.040 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2020 | 46 | 0.040 |
Why?
| | Magnetic Resonance Angiography | 1 | 2022 | 240 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 147 | 0.040 |
Why?
| | Kainic Acid | 1 | 2020 | 35 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2020 | 71 | 0.040 |
Why?
| | DNA Primers | 1 | 2001 | 514 | 0.040 |
Why?
| | Indians, North American | 1 | 2006 | 630 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2022 | 6054 | 0.040 |
Why?
| | Catheterization | 1 | 2000 | 179 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2019 | 64 | 0.040 |
Why?
| | Carbon | 1 | 2021 | 223 | 0.040 |
Why?
| | Protective Agents | 1 | 2019 | 41 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2019 | 90 | 0.040 |
Why?
| | Emtricitabine | 1 | 2020 | 174 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 99 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 162 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 2019 | 153 | 0.040 |
Why?
| | Metabolic Syndrome | 2 | 2017 | 354 | 0.040 |
Why?
| | Urinary Bladder Diseases | 1 | 2019 | 19 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2021 | 178 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 184 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 197 | 0.040 |
Why?
| | Substance Abuse Detection | 1 | 2020 | 89 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 85 | 0.040 |
Why?
| | Sample Size | 1 | 2019 | 127 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2006 | 1709 | 0.040 |
Why?
| | Group IV Phospholipases A2 | 1 | 2019 | 47 | 0.040 |
Why?
| | Biological Transport | 1 | 2020 | 417 | 0.040 |
Why?
| | Ligaments | 1 | 2019 | 60 | 0.040 |
Why?
| | Cerebellum | 1 | 2001 | 224 | 0.040 |
Why?
| | Sensation | 1 | 1999 | 53 | 0.040 |
Why?
| | Colitis, Ulcerative | 1 | 2000 | 137 | 0.040 |
Why?
| | Education | 1 | 2019 | 107 | 0.040 |
Why?
| | Pulmonary Circulation | 1 | 2021 | 430 | 0.040 |
Why?
| | Normal Distribution | 1 | 2018 | 21 | 0.040 |
Why?
| | Caspase 3 | 1 | 2019 | 246 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 142 | 0.040 |
Why?
| | Molecular Weight | 1 | 2019 | 335 | 0.040 |
Why?
| | Neuroimaging | 1 | 2021 | 263 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 515 | 0.040 |
Why?
| | Sirtuins | 1 | 2019 | 40 | 0.040 |
Why?
| | Protons | 1 | 2019 | 90 | 0.040 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 254 | 0.040 |
Why?
| | Urogenital Abnormalities | 1 | 2019 | 64 | 0.040 |
Why?
| | Receptors, AMPA | 1 | 2020 | 141 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2018 | 19 | 0.040 |
Why?
| | Metyrapone | 1 | 2018 | 2 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 519 | 0.040 |
Why?
| | Colorado | 3 | 2020 | 4527 | 0.040 |
Why?
| | Fluorescent Dyes | 1 | 2020 | 318 | 0.040 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2018 | 19 | 0.040 |
Why?
| | Computer Graphics | 1 | 2018 | 42 | 0.040 |
Why?
| | Dinitrobenzenes | 1 | 2018 | 5 | 0.040 |
Why?
| | Analgesics | 1 | 2020 | 206 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2018 | 88 | 0.040 |
Why?
| | Sirtuin 3 | 1 | 2019 | 61 | 0.040 |
Why?
| | Receptors, IgE | 1 | 2018 | 45 | 0.040 |
Why?
| | Uterus | 1 | 2019 | 215 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 858 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 283 | 0.040 |
Why?
| | Cardiovascular Diseases | 2 | 2008 | 2113 | 0.040 |
Why?
| | Ribosomes | 1 | 2019 | 186 | 0.040 |
Why?
| | Rectum | 1 | 2019 | 185 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 182 | 0.040 |
Why?
| | Abdominal Pain | 1 | 1999 | 146 | 0.040 |
Why?
| | Magnetite Nanoparticles | 1 | 2017 | 30 | 0.040 |
Why?
| | Thioredoxins | 1 | 2017 | 30 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 2135 | 0.030 |
Why?
| | Azo Compounds | 1 | 2017 | 30 | 0.030 |
Why?
| | Dronabinol | 1 | 2020 | 229 | 0.030 |
Why?
| | Organ Specificity | 1 | 2018 | 304 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2019 | 813 | 0.030 |
Why?
| | Crigler-Najjar Syndrome | 1 | 1997 | 2 | 0.030 |
Why?
| | Heterozygote | 3 | 1994 | 292 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2017 | 73 | 0.030 |
Why?
| | Glucuronosyltransferase | 1 | 1997 | 16 | 0.030 |
Why?
| | Tuberculosis | 1 | 2020 | 279 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 2018 | 377 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 114 | 0.030 |
Why?
| | Metal Nanoparticles | 1 | 2018 | 89 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 422 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1274 | 0.030 |
Why?
| | Solubility | 2 | 2008 | 247 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 362 | 0.030 |
Why?
| | Medication Adherence | 1 | 2020 | 468 | 0.030 |
Why?
| | Cell Survival | 1 | 2020 | 1119 | 0.030 |
Why?
| | Surface Properties | 1 | 2017 | 416 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 350 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 643 | 0.030 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 190 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2021 | 903 | 0.030 |
Why?
| | Exons | 2 | 1997 | 351 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2658 | 0.030 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 221 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2016 | 75 | 0.030 |
Why?
| | Genetic Linkage | 2 | 2007 | 298 | 0.030 |
Why?
| | Lipogenesis | 1 | 2016 | 61 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2018 | 188 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 98 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 666 | 0.030 |
Why?
| | Iopamidol | 1 | 2015 | 17 | 0.030 |
Why?
| | Autophagy | 1 | 2018 | 281 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 530 | 0.030 |
Why?
| | Animals, Inbred Strains | 1 | 2015 | 7 | 0.030 |
Why?
| | NF-kappa B | 1 | 2019 | 691 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 745 | 0.030 |
Why?
| | Child | 4 | 2014 | 21999 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1218 | 0.030 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2015 | 17 | 0.030 |
Why?
| | Codon | 2 | 1992 | 89 | 0.030 |
Why?
| | Heart | 1 | 2018 | 657 | 0.030 |
Why?
| | Genetic Testing | 1 | 1997 | 454 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 846 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2019 | 886 | 0.030 |
Why?
| | Histones | 1 | 2019 | 636 | 0.030 |
Why?
| | Glutathione | 1 | 2016 | 358 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2015 | 195 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 403 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 392 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2715 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 521 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2015 | 175 | 0.030 |
Why?
| | Saliva | 2 | 2006 | 244 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 436 | 0.030 |
Why?
| | Triglycerides | 1 | 2016 | 524 | 0.030 |
Why?
| | Chelation Therapy | 1 | 2013 | 11 | 0.030 |
Why?
| | Iron Chelating Agents | 1 | 2013 | 18 | 0.030 |
Why?
| | Chronic Disease | 1 | 2019 | 1788 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2841 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2017 | 769 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2010 | 2164 | 0.030 |
Why?
| | Ovarian Diseases | 1 | 2012 | 12 | 0.030 |
Why?
| | Entropy | 1 | 2012 | 40 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2020 | 1987 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1355 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2225 | 0.020 |
Why?
| | Thalassemia | 1 | 1992 | 7 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 1028 | 0.020 |
Why?
| | Ultrasonography, Doppler | 1 | 2012 | 123 | 0.020 |
Why?
| | Exome | 1 | 2013 | 231 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5769 | 0.020 |
Why?
| | Data Mining | 1 | 2012 | 117 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1100 | 0.020 |
Why?
| | Blood Cell Count | 1 | 2011 | 55 | 0.020 |
Why?
| | Transferrin | 1 | 2011 | 46 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1773 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2011 | 114 | 0.020 |
Why?
| | DNA | 3 | 1994 | 1459 | 0.020 |
Why?
| | Placenta | 1 | 2018 | 749 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 493 | 0.020 |
Why?
| | Reference Standards | 1 | 2011 | 186 | 0.020 |
Why?
| | Thermosensing | 1 | 2010 | 12 | 0.020 |
Why?
| | Ovary | 1 | 2012 | 221 | 0.020 |
Why?
| | Software Design | 1 | 2010 | 24 | 0.020 |
Why?
| | Genetics, Behavioral | 1 | 2010 | 40 | 0.020 |
Why?
| | Obesity | 1 | 2004 | 2983 | 0.020 |
Why?
| | Crosses, Genetic | 1 | 2010 | 137 | 0.020 |
Why?
| | Neurons | 1 | 2020 | 1588 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 243 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 90 | 0.020 |
Why?
| | Antisocial Personality Disorder | 1 | 2011 | 169 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 1993 | 326 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2010 | 89 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 307 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2009 | 9 | 0.020 |
Why?
| | Blood Proteins | 1 | 2011 | 252 | 0.020 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2009 | 9 | 0.020 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2010 | 89 | 0.020 |
Why?
| | Corticosterone | 1 | 2010 | 236 | 0.020 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 39 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2073 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 2008 | 54 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1484 | 0.020 |
Why?
| | New Mexico | 1 | 2008 | 92 | 0.020 |
Why?
| | Social Marketing | 1 | 2008 | 16 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2008 | 269 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 976 | 0.020 |
Why?
| | Rural Health | 1 | 2008 | 79 | 0.020 |
Why?
| | Brain Mapping | 1 | 2010 | 505 | 0.020 |
Why?
| | Pituitary Function Tests | 1 | 2007 | 2 | 0.020 |
Why?
| | Receptor Activator of Nuclear Factor-kappa B | 1 | 2007 | 9 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2008 | 187 | 0.020 |
Why?
| | Fruit | 1 | 2008 | 139 | 0.020 |
Why?
| | Sunlight | 1 | 2008 | 73 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2009 | 372 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 156 | 0.020 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2006 | 23 | 0.020 |
Why?
| | Adrenal Glands | 1 | 2007 | 78 | 0.020 |
Why?
| | Myoglobin | 1 | 2006 | 13 | 0.020 |
Why?
| | Acetaldehyde | 1 | 2006 | 17 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2007 | 69 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2006 | 30 | 0.020 |
Why?
| | Genetic Carrier Screening | 2 | 1997 | 28 | 0.020 |
Why?
| | Pituitary Gland | 1 | 2007 | 149 | 0.020 |
Why?
| | Electrophysiology | 1 | 2006 | 217 | 0.020 |
Why?
| | Osteoclasts | 1 | 2006 | 52 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2006 | 208 | 0.020 |
Why?
| | Hormones | 1 | 2006 | 142 | 0.020 |
Why?
| | Hip Prosthesis | 1 | 2006 | 47 | 0.020 |
Why?
| | Reminder Systems | 1 | 2007 | 168 | 0.020 |
Why?
| | Bone and Bones | 1 | 2008 | 316 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2006 | 284 | 0.010 |
Why?
| | Educational Status | 1 | 2008 | 484 | 0.010 |
Why?
| | Educational Measurement | 1 | 2008 | 281 | 0.010 |
Why?
| | Physical Endurance | 1 | 2006 | 277 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2006 | 216 | 0.010 |
Why?
| | Lactic Acid | 1 | 2006 | 306 | 0.010 |
Why?
| | Pedigree | 2 | 1997 | 514 | 0.010 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 56 | 0.010 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2004 | 83 | 0.010 |
Why?
| | Electromyography | 1 | 2006 | 401 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 330 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2004 | 225 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 213 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2004 | 155 | 0.010 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 808 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2004 | 455 | 0.010 |
Why?
| | Vitamin D | 1 | 2006 | 397 | 0.010 |
Why?
| | Dietary Fats | 1 | 2004 | 304 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5726 | 0.010 |
Why?
| | Patient Selection | 1 | 2004 | 692 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1374 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2008 | 852 | 0.010 |
Why?
| | Viscera | 1 | 1999 | 17 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2006 | 808 | 0.010 |
Why?
| | Child, Preschool | 2 | 2008 | 11080 | 0.010 |
Why?
| | Psychological Tests | 1 | 1999 | 141 | 0.010 |
Why?
| | Age Factors | 1 | 2006 | 3297 | 0.010 |
Why?
| | Research Design | 1 | 2004 | 1128 | 0.010 |
Why?
| | Pain Measurement | 1 | 2000 | 524 | 0.010 |
Why?
| | Cytokines | 1 | 2006 | 2090 | 0.010 |
Why?
| | Perception | 1 | 2000 | 361 | 0.010 |
Why?
| | Registries | 1 | 2004 | 2016 | 0.010 |
Why?
| | Genetics, Population | 1 | 1997 | 210 | 0.010 |
Why?
| | Prenatal Diagnosis | 1 | 1997 | 202 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 2373 | 0.010 |
Why?
| | Homozygote | 1 | 1994 | 203 | 0.010 |
Why?
| | Frameshift Mutation | 1 | 1992 | 32 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 345 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 1061 | 0.000 |
Why?
| | Infant | 1 | 1997 | 9451 | 0.000 |
Why?
|
|
Saba's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|